Literature DB >> 7307341

Ability of complement to release systemic lupus erythematosus immune complexes from cell receptors.

M E Medof, D Scarborough, G Miller.   

Abstract

Endogenous immune complexes present in sera from 10 different patients with systemic lupus erythematosus (SLE) in an active phase were allowed to bind to Raji cells; the ability of intact complement to release the cell-bound complexes from receptors was then examined. Fresh normal human serum, or, alternatively, zymosan-pretreated serum, was added to the complex-bearing Raji cells. Immune complexes remaining bound to Raji cell receptors after increasing times at 37 degrees C were quantitated by addition of 125I-labelled antiglobulin, after removal of serum by washing. In all 10 cases, complement-dependent release was observed. In parallel control studies performed under identical conditions, immune complexes prepared in vitro from bovine serum albumin (BSA) and guinea-pig anti-BSA antibody were used in place of the endogenous SLE complexes. The experimental complexes were released by fresh serum, but not by zymosan-treated serum, but not by zymosan-treated serum, when studied using either 125I-labelled anti-guinea-pig Ig or 125I-labelled complexes alone. The results suggest that intact complement can alter the immune complexes present in SLE sera and influence their interaction with receptors on lymphoid cells. The results further raise the possibility that hypocomplementaemia secondarily due to consumption of complement by immune complexes may contribute to the persistence of the complexes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307341      PMCID: PMC1537339     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  A new complement function: solubilization of antigen-antibody aggregates.

Authors:  G W Miller; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

2.  Mechanism of binding of soluble immune complexes to lymphocytes.

Authors:  A Eden; C Bianco
Journal:  Cell Immunol       Date:  1973-06       Impact factor: 4.868

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Complement as a regulator of interactions between immune complexes and cell membranes.

Authors:  G W Miller; V Nussenzweig
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

5.  Study of circulating immune complexes in thyroid diseases: comparison of Raji cell radioimmunoassay and specific thyroglobulin-antithyroglobulin radioassay.

Authors:  S Mariotti; L J DeGroot; D Scarborough; M E Medof
Journal:  J Clin Endocrinol Metab       Date:  1979-11       Impact factor: 5.958

6.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

7.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

8.  Complement-dependent release of immune complexes from the lymphocyte membrane.

Authors:  G W Miller; P H Saluk; V Nussenzweig
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

9.  Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.

Authors:  A N Theofilopoulos; F J Dixon; V A Bokisch
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

10.  Binding of soluble immune complexes to human lymphoblastoid cells. II. Use of Raji cells to detect circulating immune complexes in animal and human sera.

Authors:  A N Theofilopoulos; C B Wilson; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

View more
  6 in total

1.  In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.

Authors:  Y Inada; M Kamiyama; T Kanemitsu; H Ikegami; K Watanabe; W S Clark; Y Asai
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

2.  Effects of cobra venom factor treatment on latent feline leukemia virus infection.

Authors:  E H Kraut; J L Rojko; R G Olsen; D L Tuomari
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

3.  Normal human serum restores the expression of Fc gamma receptors in immune complex-blocked human mononuclear cells.

Authors:  J R Geffner; G Serebrinsky; M A Isturiz
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

4.  Primate erythrocyte-immune complex-clearing mechanism.

Authors:  J B Cornacoff; L A Hebert; W L Smead; M E VanAman; D J Birmingham; F J Waxman
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

5.  Differences in interaction between immune complexes and complement receptors in serum and cerebrospinal fluid.

Authors:  M E Medof; J P Antel; J J Oger; G M Prince; B G Arnason
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

6.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.